OUR VISION
To improve global healthcare by increasing the availability of biotechnology medicines.
OUR MISSION
To develop and manufacture high quality biologics at affordable prices through manufacturing innovation, state-of-the-art technologies to ensure all patient needs are addressed and met and to promote and accelerate the success of our clients.
OUR VALUES
At Eden Biologics, we value and foster an environment for continuous learning, encourage open communication and team building, building trust with our clients, and emphasize the importance of cGMP with tight CMC strategies to produce the highest quality biologics.
Eden Biologics Introduces New Chief Executive Officer, Dr. Steve Lee
Eden Biologics, Inc., a leading global biotechnology company based in Hsinchu, Taiwan, announced on September 1st, the appointment of Dr. Steve Lee, an accomplished biotech executive with broad experience and entrepreneurial leadership, as the new CEO and Director of the Board, effective immediately.
Eden Biologics’ Leading Biosimilar Program Receives Phase 3 Approval in Europe
We’ve once again achieved a huge corporate milestone and are excited to share the great news with all of you! Our EB-CLIN-1001-03 Phase 3 Clinical Trial for our leading Biosimilar Program EB1001, received approval from Hungary’s National Institute of Pharmacy and Nutrition (OGYÉI), as well as the Ethics Committee!
Eden Biologics Statement
Earlier this week, the United States Department of Justice announced that it has filed criminal charges against Racho Jordanov and Rose Lin, former employees of JHL Biotech (the predecessor to Eden Biologics), relating to alleged theft of trade secrets from Genentech.
Eden Biologics Proudly Announces Dr. Scott Liu as Board Member
Eden Biologics is honored to announce the addition of Dr. Scott Liu as a member of the Eden Board of Directors.
Eden Biologics Anticipates Initiation of Global Phase 3 in 2021 H2 for Its Denosumab Biosimilar
Eden Biologics, Inc., a global frontrunner in biological drug development and manufacturing platform technologies, today announced completion of enrollment for their Phase 1 comparative PK Clinical Trial (JHL-CLIN-1266-01) of Eden’s lead product candidate EB1001
JHL Biotech Officially Changes Name to EDEN Biologics
JHL Biotech, Inc., a global frontrunner in large-molecule biological drug development and manufacturing platform technologies, is excited to announce today that it has changed its corporate name to Eden Biologics, Inc.
Q-Sera Pty Ltd and JHL Biotech, Inc. Announce a Strategic Collaboration
Q-Sera Pty Ltd is pleased to announce a collaboration with JHL Biotech, Inc. (Taiwan) to produce high yielding recombinant ecarin for commercial scale production of RAPClot™ Rapid Serum tubes.
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company’s Australian Phase I Clinical Trial of JHL1266 in healthy subjects.